Sunday, December 21, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Ratings and Price Targets for Axsome Therapeutics

Elaine Mendonca by Elaine Mendonca
February 6, 2024
in Breaking News
0
0
SHARES
69
VIEWS
Share on FacebookShare on Twitter

As of February 6, 2024, a total of 8 analysts have recently published ratings on Axsome Therapeutics (NASDAQ:AXSM), offering a wide range of perspectives on the stock. Let’s take a closer look at their ratings and how they have evolved over the past few months.

Rating Total Ratings Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago
Bullish 4 1 0 3 0
Somewhat Bullish 4 0 3 1 0
Indifferent 0 0 0 0 0
Somewhat Bearish 0 0 0 0 0
Bearish 0 0 0 0 0

These ratings reflect the changing sentiments towards Axsome Therapeutics within the past 30 days, compared to the ratings from previous months.

In addition to the ratings, analysts also provide insights through their assessments of 12-month price targets. The average target currently stands at $131.38, with a high estimate of $180.00 and a low estimate of $108.00. This indicates a significant increase of 45.98% from the previous average price target of $90.00.

Let’s dive into some key insights from the analysts’ actions and price targets:

– Ashwani Verma from UBS has announced a Buy rating on Axsome Therapeutics, setting a current price target of $111.00.
– Leonid Timashev from RBC Capital has given an Outperform rating, with a current price target of $126.00.
– Charles Duncan from Cantor Fitzgerald has maintained an Overweight rating and set a current price target of $108.00.
– David Amsellem from Piper Sandler has raised both the Overweight rating and the price target to $113.00 from $90.00.
– Raghuram Selvaraju from HC Wainwright & Co. has maintained a Buy rating, with a high price target of $180.00.

Taking into account various sources, the average price target for Axsome Therapeutics is approximately $130.22, with a high forecast of $180.00.

These ratings and price targets provide valuable insights into the evolving sentiments and expectations of financial experts in relation to Axsome Therapeutics in the stock market.

AXSM Stock Performance: Mixed Day with Price Decrease and Pre-Market Rise

On February 6, 2024, AXSM stock exhibited mixed performances, with a slight decrease in price during regular market hours followed by a rise in pre-market trading. According to data from CNN Money, AXSM was trading near the top of its 52-week range and above its 200-day simple moving average, indicating positive price momentum.

The price of AXSM shares experienced a decrease of $1.32 since the market last closed, representing a 1.42% drop. The stock closed at $91.50, reflecting the decline. However, in pre-market trading, the stock managed to bounce back, rising by $2.50.

The fact that AXSM was trading near the top of its 52-week range suggests that the stock has been performing well compared to its historical price levels. This indicates that investors have been optimistic about the company’s prospects, leading to increased demand and a higher share price.

Furthermore, the stock being above its 200-day simple moving average is another positive sign. The 200-day moving average is a widely followed technical indicator used by traders and investors to identify the overall trend of a stock. When a stock is trading above its 200-day moving average, it suggests that the stock has been on an upward trend over the long term.

The decrease of $1.32 in the price of AXSM shares may be attributed to various factors such as market conditions, sector trends, or company-specific news.

However, the subsequent rise of $2.50 in pre-market trading indicates that there may be positive sentiment surrounding AXSM.

Investors should closely monitor AXSM’s performance throughout the trading day to gain a better understanding of the stock’s direction. It is essential to consider other factors such as news releases, earnings reports, or market trends that may impact the stock’s price. Conducting thorough research and consulting with a financial advisor can help investors make informed decisions about their AXSM holdings.

AXSM Stock Performance: Mixed Results and Potential Recovery in Earnings Per Share

On February 6, 2024, AXSM stock experienced mixed performances based on the available data from CNN Money.

The net income for AXSM in the past year was -$187.13 million, indicating a significant loss. However, compared to the third quarter of the same year, the net income improved by 7.4% to -$62.20 million.

In terms of year-on-year performance, AXSM’s net income decreased by 43.5%. However, it is worth noting that the net income increased by 7.4% since the previous quarter.

The earnings per share (EPS) for the past year was -$4.60, representing a significant loss per share. However, compared to the third quarter of the same year, the EPS improved by 14.17% to -$1.32 per share.

In terms of year-on-year performance, AXSM’s EPS decreased by 32.79%. However, the increase of 14.17% in EPS since the previous quarter shows a potential recovery in earnings per share.

It is important to note that the absence of total revenue data limits our ability to fully assess AXSM’s financial performance. Investors and analysts should closely monitor AXSM’s future financial reports to gain a more comprehensive understanding of the company’s performance.

Tags: AXSM
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Consumer Electronics Stock Bull Market

CTS Corporation Announces New 50 Million Share Repurchase Program

Food Retailers Trading online

Upgrade and Price Target Increase for Tyson Foods A Balanced Outlook on a Prominent Food Company

Food Producers Stock Exchange

Analyst Ratings for DoorDash Indicate Positive Outlook

Recommended

JD.com Stock

Pivotal Week Ahead for JD.com as Major European Acquisition and EV Launch Converge

2 months ago
Snowflake Stock

Snowflake Faces Investor Confidence Test After Executive’s Rogue Forecast

2 months ago
Fiserv Stock

Fiserv’s Strategic Expansion Meets Legal Scrutiny

3 months ago
Does_Walmart_Take_Google_Pay

Does Walmart Take Google Pay? Exploring Walmart’s Exclusive Payment Solution

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Bitcoin Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Intellia Therapeutics Faces Mounting Analyst Scrutiny Amid Regulatory Setback

Strategy Inc. Faces a Critical Index Classification Decision

DeFi Technologies Broadens Global Reach with New Listings and Products

Barrick Gold Secures Key Resolution in Mali, Paving Way for Mine Restart

Analyst Upgrade Sends Red Cat Shares Soaring

A Billion-Dollar Vote of Confidence for Standard Lithium

Trending

Tesla Stock
Automotive & E-Mobility

Tesla’s Valuation Faces Crucial Test Amid Legal Victory and Robotaxi Push

by Dieter Jaworski
December 21, 2025
0

Tesla shares are trading near their 52-week high as the company approaches a pivotal week, fueled by...

Wolfspeed Stock

Wolfspeed Secures Financial and Strategic Milestones

December 21, 2025
Textron Stock

Textron Stock Approaches Annual Peak Amid Strategic Wins

December 21, 2025
Intellia Therapeutics Stock

Intellia Therapeutics Faces Mounting Analyst Scrutiny Amid Regulatory Setback

December 21, 2025
Strategy Stock

Strategy Inc. Faces a Critical Index Classification Decision

December 21, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Tesla’s Valuation Faces Crucial Test Amid Legal Victory and Robotaxi Push
  • Wolfspeed Secures Financial and Strategic Milestones
  • Textron Stock Approaches Annual Peak Amid Strategic Wins

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com